Nanowear and Dexcom Unite to Advance Cardiometabolic Digital Diagnostics

Healthcare innovation has pivoted towards more integrated, AI-powered diagnostic solutions. Nanowear has partnered with Dexcom to combine continuous glucose monitoring with comprehensive cardiovascular biomarker analysis, enabling unprecedented real-time health insights.

The partnership between Nanowear and Dexcom has integrated the Dexcom G7 continuous glucose monitoring system with Nanowear's SimpleSense nanotechnology-enabled wearable, creating a robust platform for cardiometabolic health monitoring. This collaboration represents a significant leap in personalized digital healthcare, leveraging advanced technologies to provide comprehensive patient insights.

Nanowear's SimpleSense wearable is an FDA-cleared device that captures 120 million data points daily, utilizing cloth-based nanosensor technology to monitor critical health parameters. These include respiration rate, heart rate, blood pressure, physical activity, and lung volume. The platform's AI-driven analysis generates detailed reports for physicians, transforming raw data into actionable medical intelligence.

The Dexcom G7, an FDA-cleared continuous glucose monitoring system, can be worn on the back of the upper arm or upper buttocks and is suitable for individuals with all types of diabetes aged two and older. It provides glucose readings to a smartphone every five minutes, offering real-time metabolic tracking.

By integrating Dexcom's glucose data with Nanowear's cardiovascular biomarkers, clinical researchers can now obtain real-world, real-time cardiometabolic diagnostic assessments. This breakthrough addresses a long-standing challenge in digital health.

Venk Varadan, CEO and cofounder of Nanowear, articulated the vision behind this partnership: "The promise of digital health over a decade ago was precision medicine and individualized care that would save patients, providers and payers time and money while promoting better outcomes and experience. Gen 1 and Gen 2 solutions, while successful in building awareness, never truly accomplished this goal holistically and diagnostically. Being able to passively quantify the relationship via AI between glucose tolerance/insulin sensitivity and hypertension, arrhythmia, sleep apnea, heart failure, etc., is going to be a proven cardiometabolic solution in precision medicine and individualized care — and Nanowear can now do that."

The partnership builds on both companies' recent innovations, including Nanowear's FDA clearance for AI-enabled diagnostic tools and Dexcom's strategic investments and expansions in digital health monitoring technologies.